Program : GBR 500 – Monoclonal Antibody (mAB)
|
Phase I
|
|
|
| Target /Indication |
A monoclonal antibody directed against VLA-2, a human adhesion molecule. The molecule has potential for the treatment of a broad range of inflammatory and autoimmune diseases, which includes Multiple Sclerosis and Inflammatory Bowel Disorder. |
| Highlights |
| |
|
GBR 500 has a novel mechanism of action and provides a first in class opportunity. |
| |
|
It has a favourable safety profile. |
| |
|
There is also potential to expand indications to oncology based on in-vitro and in-vivo studies undertaken with GBR 500. |
| |
|
GBR 500 is currently undergoing Phase I trials in the US. |
| |
|
Glenmark is now the first Indian company to have a novel biologic molecule in the clinics that could be marketed globally. |
|
| Market Opportunity |
|
| Potential Peak Sales
|
USD 1 billion |
|